Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.

European journal of neurology·2026
Same author

Spinal cord reserve is associated with multi-dimensional clinical resilience in multiple sclerosis.

Journal of neurology·2026
Same author

Deconfounded, quantitative microbiome profiling identifies robust multiple sclerosis markers and clinical covariate associations.

Gut microbes·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis.

Scientific reports·2026
Same author

Data-driven hypothesis discovery from disease trajectories in multiple sclerosis.

Frontiers in immunology·2026

Related Experiment Video

Updated: May 3, 2026

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

1.1K

Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.

Melissa Cambron1, Jop Mostert, Patrick Haentjens

  • 1Department of Neurology, University Hospital Brussel, Center for Neurosciences Vrije Universiteit Brussel (VUB) UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium. melissa.cambron@gmail.com.

Trials
|January 28, 2014
PubMed
Summary
This summary is machine-generated.

This clinical trial investigates if fluoxetine can slow progressive multiple sclerosis (MS) by potentially protecting axons. Researchers will assess fluoxetine

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
11:27

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

17.6K

Related Experiment Videos

Last Updated: May 3, 2026

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

1.1K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
11:27

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

17.6K

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Pharmacology

Background:

  • Current disease-modifying treatments are ineffective for progressive multiple sclerosis (MS), a condition characterized by widespread axonal degeneration.
  • Suspected mechanisms in MS axonal degeneration include impaired energy metabolism, glutamate toxicity, and reduced cerebral blood flow.
  • Fluoxetine may offer neuroprotection in MS by stimulating axonal energy metabolism, promoting brain-derived neurotrophic factor, and dilating cerebral arterioles.

Purpose of the Study:

  • To test the hypothesis that fluoxetine can slow the progression of MS.
  • To evaluate the potential neuroprotective effects of fluoxetine in progressive MS patients.

Main Methods:

  • The FLUOX-PMS trial is a multi-center, randomized, double-blind, placebo-controlled study.
  • 120 patients with secondary or primary progressive MS will receive either 40 mg of fluoxetine daily or a placebo for 108 weeks.
  • Primary endpoint: time to confirmed disease progression (20% increase in 25-Foot Walk or 9-Hole Peg Test); secondary endpoints include ambulation, cognition, fatigue, and imaging.

Main Results:

  • Results are pending as the trial is designed to gather information on fluoxetine's efficacy.
  • The study will provide data on fluoxetine's impact on key MS progression markers.

Conclusions:

  • The FLUOX-PMS trial aims to determine if fluoxetine exhibits neuroprotective properties in progressive MS.
  • Findings will inform potential new therapeutic strategies for progressive MS.